Fortrea Holdings Inc
FTRE: XNAS (USA)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
$91.50 | Skrgvc | Bpwvsqbzd |
Fortrea: Healthy Clinical Trial Outsourcing Demand Supports Backlog Growth; Shares Undervalued
Fortrea reported solid third-quarter results highlighted by revenue of $776 million. The company is tracking our expectations and we maintain our fair value estimate of $35.50 per share. We view shares as undervalued, currently trading about 8% below our fair value estimate. Investors reacted positively to Fortrea’s results, sending the stock up over 10%.